IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is among the best healthcare stocks with the highest upside, according to JMP analyst Silvan Tuerkcan, who maintains a Buy rating and $45 price target. The company also received a Buy rating from J.P. Morgan analyst Anupam Rama with a $74 price target.

Analysts are optimistic about IDEAYA Biosciences, Inc. (NASDAQ:IDYA) due to promising developments with its lead asset, darovasertib, expected to create significant value. Darovasertib targets patients with uveal melanoma, a rare eye cancer with unmet medical needs.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) focuses on developing precision medicine for oncology, including the protein kinase C inhibitor IDE196 for genetically defined cancers. While IDYA is a potential investment, some AI stocks may offer greater upside potential and less downside risk.

For more insights on stocks with potential growth, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey.

Read more at Yahoo Finance: Citizens JMP Remains Bullish on IDEAYA Biosciences (IDYA)